WeLeader Biomedical (7713.TWO) Earnings Analysis
WeLeader Biomedical (7713.TWO) next reports earnings on 2026-08-18. Last quarter (2026-02-26) it beat with EPS 1.27 TWD vs 1.05 TWD est (+21%). It has beaten estimates in 5/5 recent quarters (100%). Trailing P/E 14.51.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 7713.TWO next report earnings?
| Next earnings date | 2026-08-18 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | n/a |
7713.TWO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-26 | 1.27 TWD | 1.05 TWD | +21% | Beat |
| 2025-11-07 | 1.31 TWD | 1.08 TWD | +21.3% | Beat |
| 2025-08-11 | 1.1 TWD | 1.05 TWD | +4.8% | Beat |
| 2025-05-08 | 0.94 TWD | 0.94 TWD | 0% | Beat |
| 2024-12-31 | 0.967 TWD | 0.96 TWD | +0.7% | Beat |
| 2024-09-30 | 1.06 TWD | n/a | n/a | n/a |
Beat rate: 5/5 (100%) over reported quarters with consensus data.
7713.TWO valuation and analyst view
| Trailing P/E | 14.51 |
|---|---|
| Trailing EPS | 4.87 TWD |
| Price / book | 2.83 |
| Dividend yield | 5.82% |
| Market cap | 3.22B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is WeLeader Biomedical (7713.TWO)'s next earnings date?
WeLeader Biomedical is next scheduled to report on 2026-08-18.
Did 7713.TWO beat earnings last quarter?
In its 2026-02-26 report, 7713.TWO posted EPS of 1.27 TWD versus a 1.05 TWD estimate — a beat of 21%.
What is 7713.TWO's earnings track record?
Over the last 5 reported quarters with consensus data, 7713.TWO beat estimates 5 times (100%).
What is 7713.TWO's current P/E ratio and EPS?
7713.TWO trades at a trailing P/E of 14.51 on trailing EPS of 4.869591133874956 TWD.
What do analysts rate 7713.TWO?
7713.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.